Option chain shows key data for 's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for .

 (GNPX) Stock, Option Chain

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Lattice Semiconductor

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Exclusives

AAPL

AMZN

DRUG

GLMD

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

movers image

ANRO

APVO

CHSN

CNSP

DBGI

DBVT

ENPH

ENSC

FAMI

MBIO

PHUN

PIXY

XXII

ZPTA

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

Genprex Inc

Press Releases

Genprex to Participate in 2024 BIO Europe Conference

Small Cap

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Contracts

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex to Participate at BIO Europe Spring 2025

Aptevo Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Theriva Biologics

HC Wainwright & Co.

Dawson James

Screenshot 2023-07-10 at 5.56.06 PM

Biotech

General

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Comments

(GNPX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga